Wockhardt gains 4% on filing for DCGI’s approval for its insulin injection

Wockhardt is also developing additional insulin analogs and GLP-1 agonists to provide advanced diabetes care solutions

Subscribe To Our Free Newsletter

All News, Business Standard All News